Molecular Testing in Breast Cancer Current Status and Future Directions

被引：19

作者：

Sun, Lulu ^{[1
]}

Wu, Ariel ^{[1
]}

Bean, Gregory R. ^{[2
]}

Hagemann, Ian S. ^{[1
]}

Lin, Chieh-Yu ^{[1
]}

机构：

[1] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO USA

[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA

来源：

JOURNAL OF MOLECULAR DIAGNOSTICS | 2021年 / 23卷 / 11期

关键词：

LATE DISTANT RECURRENCE; ENDOCRINE THERAPY; ONCOTYPE DX; PAM50; RISK; POSTMENOPAUSAL WOMEN; TREATMENT DECISIONS; 70-GENE SIGNATURE; AMERICAN SOCIETY; EXPRESSION ASSAY; GENE-EXPRESSION;

D O I：

10.1016/j.jmoldx.2021.07.026

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Molecular testing in breast cancer is a rapidly developing field that is becoming increasingly integral to patient care. This article provides an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multigene assays for invasive breast cancer (Oncotype DX, MammaPrint, Prosigna, and Breast Cancer Index) and ductal carcinoma in situ (Oncotype DX DCIS and DCISionRT) and companion tests to detect PIK3CA mutations and NTRK fusions. The various assays related to immune checkpoint inhibitors, consisting of immunohistochemistry with antieprogrammed death-ligand 1 antibodies SP142 and 22C3 and detection of microsatellite instability, mismatch repair deficiency, and tumor mutational burden are also discussed. Finally, the practical utility and hopeful promise of next-generation sequencing panels and circulating tumor (cellfree) DNA assays are evaluated. This review should serve as a useful and practical reference for practicing pathologists, molecular pathologists, clinicians, and researchers.

引用

页码：1422 / 1432

页数：11

共 74 条

[31]

Juric D, 2018, ALPELISIB THORN FULV, pGS3

[32]

Kalinsky K., 2020, SAN ANTONIO BREAST C

[33] Biomarker assessment and molecular testing for prognostication in breast cancer [J].

Kos, Zuzana ;

Dabbs, David J. .

HISTOPATHOLOGY, 2016, 68 (01) :70-85

[34] Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial [J].

Liu, Shuzhen ;

Chapman, Judy-Anne W. ;

Burnell, Margot J. ;

Levine, Mark N. ;

Pritchard, Kathleen I. ;

Whelan, Timothy J. ;

Rugo, Hope S. ;

Albain, Kathy S. ;

Perez, Edith A. ;

Virk, Shakeel ;

Barry, Garrett ;

Gao, Dongxia ;

O'Brien, Patti ;

Shepherd, Lois E. ;

Nielsen, Torsten O. ;

Gelmon, Karen A. .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (02) :439-448

[35] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer [J].

Ma, Cynthia X. ;

Bose, Ron ;

Gao, Feng ;

Freedman, Rachel A. ;

Telli, Melinda L. ;

Kimmick, Gretchen ;

Winer, Eric ;

Naughton, Michael ;

Goetz, Matthew P. ;

Russell, Christy ;

Tripathy, Debu ;

Cobleigh, Melody ;

Forero, Andres ;

Pluard, Timothy J. ;

Anders, Carey ;

Niravath, Polly Ann ;

Thomas, Shana ;

Anderson, Jill ;

Bumb, Caroline ;

Banks, Kimberly C. ;

Lanman, Richard B. ;

Bryce, Richard ;

Lalani, Alshad S. ;

Pfeifer, John ;

Hayes, Daniel F. ;

Pegram, Mark ;

Blackwell, Kimberly ;

Bedard, Philippe L. ;

Al-Kateb, Hussam ;

Ellis, Matthew J. C. .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5687-5695

[36] A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer [J].

Ma, Xiao-Jun ;

Salunga, Ranelle ;

Dahiya, Sonika ;

Wang, Wilson ;

Carney, Erin ;

Durbecq, Virginie ;

Harris, Adrian ;

Goss, Paul ;

Sotiriou, Christos ;

Erlander, Mark ;

Sgroi, Dennis .

CLINICAL CANCER RESEARCH, 2008, 14 (09) :2601-2608

[37] Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J].

Marabelle, Aurelien ;

Fakih, Marwan ;

Lopez, Juanita ;

Shah, Manisha ;

Shapira-Frommer, Ronnie ;

Nakagawa, Kazuhiko ;

Chung, Hyun Cheol ;

Kindler, Hedy L. ;

Lopez-Martin, Jose A. ;

Miller, Wilson H., Jr. ;

Italiano, Antoine ;

Kao, Steven ;

Piha-Paul, Sarina A. ;

Delord, Jean-Pierre ;

McWilliams, Robert R. ;

Fabrizio, David A. ;

Aurora-Garg, Deepti ;

Xu, Lei ;

Jin, Fan ;

Norwood, Kevin ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2020, 21 (10) :1353-1365

[38] Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review [J].

Merker, Jason D. ;

Oxnard, Geoffrey R. ;

Compton, Carolyn ;

Diehn, Maximilian ;

Hurley, Patricia ;

Lazar, Alexander J. ;

Lindeman, Neal ;

Lockwood, Christina M. ;

Rai, Alex J. ;

Schilsky, Richard L. ;

Tsimberidou, Apostolia M. ;

Vasalos, Patricia ;

Billman, Brooke L. ;

Oliver, Thomas K. ;

Bruinooge, Suanna S. ;

Hayes, Daniel F. ;

Turner, Nicholas C. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) :1631-+

[39] Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) [J].

Miles, D. W. ;

Gligorov, J. ;

Andre, F. ;

Cameron, D. ;

Schneeweiss, A. ;

Barrios, C. H. ;

Xu, B. ;

Wardley, A. M. ;

Kaen, D. ;

Andrade, L. ;

Semiglazov, V. ;

Reinisch, M. ;

Patre, M. ;

Morales, L. ;

Russell, K. ;

Donica, M. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2020, 31 :S1147-S1148

[40] PD-L1 Expression in Triple-Negative Breast Cancer [J].

Mittendorf, Elizabeth A. ;

Philips, Anne V. ;

Meric-Bernstam, Funda ;

Qiao, Na ;

Wu, Yun ;

Harrington, Susan ;

Su, Xiaoping ;

Wang, Ying ;

Gonzalez-Angulo, Ana M. ;

Akcakanat, Argun ;

Chawla, Akhil ;

Curran, Michael ;

Hwu, Patrick ;

Sharma, Padmanee ;

Litton, Jennifer K. ;

Molldrem, Jeffrey J. ;

Alatrash, Gheath .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (04) :361-370

← 1 2 3 4 5 6 7 8 →